drugset / Trial / NCT04456777

Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia

NCT04456777

Phase 0 Unknown 120 enrolled Alen Greš
RandomizedParallel-groupSingle-blindTreatment

Summary

Research goals: 1. Examination of the relationship between the use of vortioxetine and cognitive efficacy in patients with schizophrenia. 2. Examination of the association between the use of vortioxetine and the presence depressive symptoms, physical and social anhedonia in patients with the disease from schizophrenia. 3. Examining the association between vortioxetine use and quality of life (functional recovery) in patients with schizophrenia Expected results (hypotheses) 1. Patients with schizophrenia treated with additional therapy vortioxetine will show better cognitive achievement in memory (short-term and long-term), attention, logical reasoning and reasoning, speed of information processing, processing of visual and sound information, language and speech in relation to patients without additional intervention. 2. Patients with schizophrenia treated with additional therapy vortioxetine will have a less pronounced presence of depressive symptoms, physical and social anhedonia in relation to untreated patients with additional vortioxetine therapy. 3. Patients with schizophrenia who were treated with additional therapy vortioxetine will have a better quality of life, ie. better functional recovery

Timeline

Start
2020-07-01
Primary completion
2022-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg

Indications